Abstract
Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established. In this context, the aim of the present study was to evaluate the circulating ESR1 mutation frequency at the end of adjuvant treatment and after relapse. This monocentric retrospective study was based on available stored plasmas and included all early breast cancer patients who completed at least 2 years of AI adjuvant treatment and experienced a documented relapse after the end of their treatment. Circulating ESR1 mutations (D538G, Y537S/N/C) were assessed by droplet digital PCR in plasma samples taken at the end of adjuvant treatment, at time of relapse and at time of progression under first line metastatic treatment. A total of 42 patients were included, with a median adjuvant AI exposure of 60 months (range 41-85). No circulating ESR1 mutation was detectable at the end of AI adjuvant therapy. At first relapse, 5.3% of the patients (2/38) had a detectable circulating ESR1 mutation. At time of progression on first-line metastatic treatment, 33...Continue Reading
References
Mar 4, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Corrinne V Segal, Mitch Dowsett
May 23, 2015·International Journal of Cancer. Journal International Du Cancer·David SefriouiFlorian Clatot
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Oct 6, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Takashi TakeshitaHirotaka Iwase
Nov 13, 2015·Science Translational Medicine·Gaia SchiavonNicholas C Turner
May 14, 2016·Nature Communications·Jill M SpoerkeMark R Lackner
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charlotte FribbensNicholas C Turner
Aug 18, 2016·JAMA Oncology·Sarat ChandarlapatyMary Ellen Moynahan
Nov 2, 2016·Oncotarget·Florian ClatotFrédéric Di Fiore
Feb 25, 2017·Nature Reviews. Cancer·Jonathan C M WanNitzan Rosenfeld
Oct 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C FribbensN Turner
Citations
Jun 13, 2019·Expert Review of Molecular Diagnostics·Marcela CarausuLuc Cabel
Jul 19, 2019·Cancer·Derek DustinSuzanne A W Fuqua
Sep 5, 2019·Journal of Clinical Medicine·Ai Hironaka-MitsuhashiAkihiko Suto
Aug 29, 2020·Expert Review of Molecular Diagnostics·Laure Cayrefourcq, Catherine Alix-Panabières
Dec 20, 2018·Nature Reviews. Clinical Oncology·Juliet Richman, Mitch Dowsett
Feb 6, 2020·Breast Cancer Research and Treatment·Tomoko ShibayamaShunji Takahashi
Jun 18, 2020·Cancer Management and Research·Hao Liao, Huiping Li
Dec 5, 2019·Cancers·Irene De SantoLuca Malorni
Dec 17, 2020·International Journal of Molecular Sciences·Marta Tellez-GabrielMaria Perander
Jan 2, 2021·Frontiers in Oncology·Hao LiaoHuiping Li
Nov 14, 2020·Cancer Research·Spencer ArnesenJason Gertz
Feb 5, 2021·Cancers·Dimitra StergiopoulouEvi Lianidou
Mar 18, 2021·Future Oncology·Charlene KayArran K Turnbull
Mar 25, 2021·Journal of Cancer Research and Clinical Oncology·Jeffrey Chun Hin ChanWilliam C Cho
Feb 12, 2020·Archives of Pathology & Laboratory Medicine·Timothy Kwang Yong Tay, Puay Hoon Tan
May 29, 2021·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yinxi ChenShuqun Zhang
Nov 6, 2021·Molecular Biology Reports·Flávia MirandaFernando Schmitt
Dec 17, 2021·Scientific Reports·Violette AlloucheryFlorian Clatot